Disposition of Patients in the Atherogenic Dyslipidemia Study

Slides:

Advertisements

Similar presentations

Robert M. Guthrie, MD Professor of Emergency Medicine

Advertisements

Slide Source: Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial Baseline, Mean (SD) Time-Weighted Average.

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

Downloaded from Slide 1 Ezetimibe Coadministered with Atorvastatin in Patients with Hypercholesterolemia and Coronary Heart.

Philip J. Barter, et al. Circulation 2011;124:

Baseline Characteristics of Individuals From the General Population by Quartiles of Triglyceride Levels a Børge G. Nordestgaard, et al. JAMA 2007;298:

© 2003, Wellsource Inc. Effect of Ketogenic Diet on Lipid Levels (shown is LDL-C) In this group of 141 children followed for 6 months, a ketogenic diet.

Baseline Characteristics of Cases, Controls, and Entire VA-HIT Population James D. Otvos, et al, Circulation 2006;113:

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Slide Source: Lipids Online Slide Library ASTEROID Population at Baseline (n=507) Patients Completing (n=349) Patients Not Completing.

Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:

Characteristics of Patients With CHF Ulf Landmesser et al Circ. 2005; 111:

Study Flow Diagram Holvoet P, et al. JAMA 2008;299: The Figure shows the selection of 1889 participants who did not have metabolic syndrome at year.

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:

Slide Source: Lipids Online Slide Library Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Nissen SE et al. JAMA.

Parameters BD PP CP TC (mg. dl-l) ± * ± 5.8

Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller MD,

Krill oil supplementation lowers serum triglycerides without increasing low-density lipoprotein cholesterol in adults with borderline high or high triglyceride.

Should we move from Lipids to Lipoproteins, from Dyslipidemia to Dyslipoproteinemia in future guidelines for CVD?

Copyright © 2002 American Medical Association. All rights reserved.

ASSOCIATIONS OF METABOLIC SYNDROME COMPONENTS WITH CRITERIA FOR THE CLINICAL DIAGNOSIS OF THE METABOLIC SYNDROME AS PROPOSED BY THE NCEP-ATP III Metabolic.

Treatment LDL-C: baseline (mg/dL) LDL-C: 24 mo (mg/dL) p

Dyslipidemia and the Risk of Developing Hypertension in a Working‐Age Male Population by Toshiaki Otsuka, Hirotaka Takada, Yasuhiro Nishiyama, Eitaro Kodani,

Oxford Niacin Trial.

The ASSERT Study.

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Cholesterol and blood pressure values at baseline and after 15 days of dark-chocolate and white-chocolate consumption Characteristic Dark chocolate before.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.

Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

Effect of evolocumab on lipoprotein particles

Figure 5 Risk factor control in the intensive treatment group

TNT post hoc analysis: Improvement between baseline and final visit in estimated GFR by treatment group End point 10-mg atorvastatin 80-mg atorvastatin.

Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol.

Radical New Concepts in Lipid Management

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.

Fellström BC, et al. N Engl J Med 2009;360:1455-7

Subject Characteristics

Hajer GR et al. Atherosclerosis 2009;202:216-24

Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:

Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment Robert Dufour,

HARMONIZE Trial design: Patients with hyperkalemia (K ≥5.1 mEq/L) were randomized in a 1:1:1:1.7 fashion to receive sodium zirconium cyclosilicate (ZS)

Stephen J. Nicholls, MBBS, PhD; E

Clinical Characteristics and Atheroma Burden of Subjects at Baseline Stratified According to Gender Nicholls SJ. et al. J Am Coll Cardiol 2007;49:

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

Flow of Patients Through the Trial

Flow of Patients Through Trial

Study Participant Flow

Baseline Characteristics, Blood Pressures, and Laboratory Values

RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.

Baseline Characteristics of the Subjects*

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

The complications of obesity according to the values of BMI and waist circumference in an obese population of Tangier Nadia HAMJANE 1, Fatiha BENYAHYA1,2,

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Characteristics of Large Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]

RECORD Study: Enrollment and Outcomes

Obese gestational diabetes mellitus (GDM) women demonstrate significant dyslipidemia at 26 weeks of gestation compared to obese women without diabetes.

Forest plot of CIMT progression rate for atorvastatin treatment versus placebo for 3 years by baseline serum 25-hydroxyvitamin D status. Forest plot of.

Titration activities from baseline up to 6 and 12 months follow-up in nurse-coordinated care (NCC) versus usual care patients. X-as: patients (percentage),

TNT diabetes analysis: Baseline and final LDL cholesterol levels

Relationship between selected metabolic parameters and the primary composite end point. Relationship between selected metabolic parameters and the primary.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

Flow of study participants

III. Treating dyslipidemias

Individual lipid measures for high-carbohydrate (n=10) and low-carbohydrate (n=10) ultra-endurance athletes. Individual lipid measures for high-carbohydrate.

LDL-c reductions below 1

© The Author(s) Published by Science and Education Publishing.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Presentation transcript:

Disposition of Patients in the Atherogenic Dyslipidemia Study Steven E. Nissen, et al. JAMA 2007;297:1362-1373

Disposition of Patients in the Hypercholesterolemia Study Steven E. Nissen, et al. JAMA 2007;297:1362-1373

Baseline Demographic Characteristics and Biochemical Parameters (Safety Population) Steven E. Nissen, et al. JAMA 2007;297:1362-1373

Atherogenic Dyslipidemia Study: Absolute and Percentage Changes in Laboratory Parameters and Blood Pressure From Baseline Until Follow-up Visit Steven E. Nissen, et al. JAMA 2007;297:1362-1373

Hypercholesterolemia Study: Absolute and Percentage Changes in Laboratory Parameters and Blood Pressure From Baseline Until Final Follow-up Visit Steven E. Nissen, et al. JAMA 2007;297:1362-1373

Hypercholesterolemia Study: Additional Effects of LY518674 After Randomization to Atorvastatin (Percentage Change From 4 Weeks to End of Treatment) Steven E. Nissen, et al. JAMA 2007;297:1362-1373

Atherogenic Dyslipidemia Study: Laboratory Safety Parameters* Steven E. Nissen, et al. JAMA 2007;297:1362-1373

Hypercholesterolemia Study: Laboratory Safety Parameters* Steven E. Nissen, et al. JAMA 2007;297:1362-1373

Post Hoc Analysis of Relationship Between Levels of Triglycerides and Low-Density Lipoprotein Cholesterol (LDL-C) Steven E. Nissen, et al. JAMA 2007;297:1362-1373